Activity Dates: 02/26/2020 - 12/03/2020
This self-study activity serves as an educational tool for pharmacists seeking Board Certified Psychiatric Pharmacist (BCPP) Recertification credit and other pharmacists and health care providers seeking advanced education in patient management, disease state management, information management, and health policy and practice management in the field of psychiatric pharmacy.
The articles selected by CPNP Recertification Editorial Board for the Literature Analysis are based on a 7-year curriculum. This curriculum is developed using the Board of Pharmaceutical Specialties' Content Outline for the Psychiatric Pharmacy Specialty Certification Examination as a guideline. Since CPNP became the sole BCPP Recertification provider in 2008, the articles are chosen to cover the three content domains - Domain I: Patient Management, Domain 2: Information Management, Domain 3: Health Policy and Practice Management.
The Literature Analysis is a self-study, online only, application-based continuing pharmacy education (CPE) activity. An application-based CPE activity requires that participants apply the information learned. The examination for this product often features case studies requiring that the participant apply the principles learned through the readings. The Literature Analysis includes:
To satisfactorily complete the Literature Analysis and receive 10 hours of BCPP Recertification and ACPE credit, candidates must meet the following requirements:
You will proceed through the following steps to satisfactorily complete this course:
Participants successfully passing the required assessment/examination will obtain both ACPE and BCPP recertification credit. Credit is awarded in the calendar year the assessment is completed. ACPE credit is reported through CPE Monitor within days of examination submission, while BCPP recertification credit is reported to BPS within 6 weeks after the examination deadline.
AAPP has invested in supporting the most popular web browsers and leveraging software that our members use daily. Beyond PDF downloads, the rest of the system is built on HTML5, a technology that most up-to-date browsers will support. To access AAPP course materials online, you will need:
AAPP web sites no longer fully support Microsoft Internet Explorer or Windows 8.1 and older. We cannot guarantee that the site will function perfectly on every device and configuration, but using the latest version of the software above will greatly improve your experience.
Article Number | Topic | Article and Learning Objectives |
---|---|---|
1 |
Bipolar Guidelines (ONLY these Sections: Intro, 3-5 and 8) |
(ONLY these Sections: Intro, 3-5 and 8) Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018 Mar;20(2):97-170. doi: 10.1111/bdi.12609.
|
2 |
Information |
Detterbeck FC, Gould MK, Lewis SZ, Patel S. Extending the reach of evidence-based medicine: A proposed categorization of lower-level evidence. Chest. 2018;2:498-506. doi:10.1016/j.chest.2017.09.006
|
3 |
PTSD |
Thal SB, Lommen MJJ. Current perspective on MDMA-assisted psychotherapy for posttraumatic stress disorder. J Contemp Psychother. 2018;48:99–108. doi:10.1007/s10879-017-9379-2 and Thal SB, Lommen MJJ. Correction to: Current perspective on MDMA-assisted psychotherapy for posttraumatic stress disorder. J Contemp Psychother. 2018;48(2):109. doi:10.1007/s10879-018-9382-2
|
4 |
Pain |
Krebs EE, Graveley A, Nugent S, et al. Effect of opioid vs nonopioid medications on pain-related function in patients with chronic back pain or hip or knee osteoarthritis pain: The SPACE randomized clinical trial. JAMA. 2018;319(9):872-882. doi:10.1001/jama.2018.0899
|
5 |
Regulatory |
Boudes PF. Risk evaluation and mitigation strategies (REMSs): Are they improving drug safety? A critical review of REMSs requiring elements to assure safe use (ETASU). Drugs R D. 2017;17(2):245–254. doi:10.1007/s40268-017-0175-y
|
6 |
Elderly |
Richardson K, Fox C, Maidment I, et al. Anticholinergic drugs and risk of dementia: case-control study [published correction appears in BMJ. 2019 Oct 31;367:l6213]. BMJ. 2018;361:k1315. Published 2018 Apr 25. doi:10.1136/bmj.k1315 and Supplemental material (eTable 1)
|
7 |
Professional Education Methods |
Molander R, Hodgkins K, Johnson C, White A, Frazier E, Krahn D. Interprofessional education in patient aligned care team primary care-mental health integration. Fed Pract. 2017;34(6):40–48.
|
8 |
Eating Disorders |
Guerdjikova AI, Mori N, Casuto LS, McElroy SL. Binge eating disorder. Psychiatr Clin North Am. 2017;40(2):255–266. doi:10.1016/j.psc.2017.01.003
|
9 |
Health Literacy |
Thorsteinsson EB, Bhullar N, Williams E, Loi NM. Schizophrenia literacy: the effects of an educational intervention on populations with and without prior health education. J Ment Health. 2019;28(3):229–237. doi:10.1080/09638237.2018.1521923
|
The College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The Literature Analysis product is an application-based program approved for 10 hours of ACPE credit. To receive ACPE credit, pharmacists completing this programming are required to complete an evaluation of the course as well as pass an online examination. BCPP Recertification credit is earned and reported within the year the assessment is successfully completed.
Board Certified Psychiatric Pharmacists (BCPPs) may also receive 10 hours of BCPP Recertification Credit for the Literature Analysis upon successful completion of an online examination.
AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.
2020 CPNP Recertification Editorial Board Disclosures
Mary C. Borovicka, PharmD, BCPP, BCPS Associate Professor University of Toledo College of Pharmacy and Pharmaceutical Sciences Cleveland, OH External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: Ohio Pharmacists Association - LAI and naltrexone training inj |
Beth DeJongh, PharmD, BCPP, BCPS Recertification Editorial Board Vice Chair Pharmacist Concordia University Wisconsin Mequon, WI No Relevant Financial Relationships to Disclose |
Sara E. Dugan, PharmD, BCPP, BCPS Associate Professor Northeast Ohio Medical University College of Pharmacy and Medicine Rootstown, OH Educational Grants, Research Grants or Contracts: Ohio Colleges of Medicine Government Research Center, Northeast Ohio Medical University College of Medicine Department of Psychiatry |
Clayton D. English, PharmD, BCPS, BCPP, BCGP |
Michelle L. Geier, PharmD, BCPP Psychiatric Clinical Pharmacist Supervisor San Francisco Department of Public Health San Francisco, CA No Relevant Financial Relationships to Disclose |
Rebecca Graham, PharmD, BCPP Clinical Pharmacy Specialist - Mental Health Corporal Michael J. Crescenz VA Medical Center in Philadelphia Philadelphia, PA No Relevant Financial Relationships to Disclose |
Courtney A. Iuppa, PharmD, BCPP Clinical Pharmacy Manager & Residency Program Director Center for Behavioral Medicine Kansas City, MO No Relevant Financial Relationships to Disclose |
Rex S. Lott, PharmD, BCPP BCPP Program Director Professor Emeritus of Pharmacy Practice Idaho State University - College of Pharmacy Meridian, ID No Relevant Financial Relationships to Disclose |
Monica Mathys, PharmD, BCPP, BCGP Associate Professor Texas Tech University School of Pharmacy Dallas, TX Non-Financial Interests: CPNP Foundation Board member |
Sarah T. Melton, PharmD, BCPP, BCACP, FASCP Recertification Editorial Board Chair Professor of Pharmacy Practice Gatton College of Pharmacy Johnson City, TN Non-Financial Interests: One Care of Southwest Virginia |
Thea R. Moore, PharmD, BCPP Associate Professor University of South Florida Tampa, FL Educational Grants, Research Grants or Contracts: Agency for Health Care Administration |
Jessica L. Mulhollan, PharmD, BCPP Psychiatric Clinical Pharmacy Specialist Cleveland Clinic Marymount Hospital Garfield Heights, OH No Relevant Financial Relationships to Disclose |
Sandra Mullen, PharmD, BCPP Clinical Pharmacy Specialist - Psychiatry VCU Health Systems Richmond, VA Non-Financial Interests: Lambda Kappa Sigma Grand Council (Executive Board) |
Stephanie Nichols, PharmD, BCPP, BCPS, FCCP Associate Professor of Pharmacy Practice Husson University Saco, ME Non-Financial Interests: Member of the New England Comparative Effectiveness Public Advisory Committee of the Institute for Clinical and Economic Review, Maine Independent Clinical Information Service Academic Detailing Advisory Committee |
Sarah J. Popish, PharmD, BCPP Academic Educator Department of Veterans Affairs Vallejo, CA No Relevant Financial Relationships to Disclose |
Megan M. Sarashinsky, PharmD, BCPP Clinical Pharmacy Specialist CJW Medical Center Richmond, VA No Relevant Financial Relationships to Disclose |
Andrea Winterswyk, PharmD, BCPS, BCPP Mental Health Clinical Pharmacy Specialist Boise Veterans Affairs Medical Center Boise, ID No Relevant Financial Relationships to Disclose |
Kara R. Wong, PharmD, BCPP Clinical Pharmacy Specialist, Mental Health; PGY2 Psychiatric Pharmacy Residency Program Director Minneapolis VA Health Care System Minneapolis, MN No Relevant Financial Relationships to Disclose |
All relevant relationships have been mitigated.
Off-Label Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA (see faculty information). The opinions expressed in the educational activity do not necessarily represent the views of AAPP and any educational partners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
It is the policy of AAPP to ensure independence, balance, objectivity, scientific rigor, and integrity in continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer’s package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.
Fair balance is achieved through ongoing and thorough review of all materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by AAPP for any product or manufacturer identified.
It is the policy of CPNP to ensure independence, balance, objectivity, scientific rigor, and integrity in their continuing education activities.
Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse effects, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer's package insert for information concerning recommended dosage and potential problems or cautions before dispensing or administering the drug or using the drug delivery system.
Fair balance is achieved through ongoing and thorough review of all materials produced before educational offerings. Approval of credit for this continuing education activity does not imply endorsement by CPNP for any product or manufacturer identified.
In accordance with the Food and Drug Administration (FDA), it is disclosed that there is the potential for discussions concerning off-label uses of a commercial product/devices during this educational activity.
Any person who may contribute to the content of this continuing education activity must disclose significant relationships (and any known relationships of their spouse/partner) with commercial companies whose products or services are discussed in this activity. Significant relationships include receiving research grants, consultant fees, travel, other benefits from a commercial company, or having a self-managed equity interest in a company.
Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.
CPNP planners and managers have no relationships to disclose related to the content of this CE activity.